EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
126 hedge funds and large institutions have $209M invested in Eagle Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 47 increasing their positions, 50 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
126
Holders Change
-27
Holders Change %
-17.65%
% of All Funds
1.99%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
47
Reduced
50
Closed
39
Calls
$56K
Puts
$10K
Net Calls
+$46K
Net Calls Change
+$21K
Top Buyers
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$5.75M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.67M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$3.21M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.99M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.33M |
Top Sellers
| 1 |
BlackRock
New York
|
-$16.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$5.94M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$4.72M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.21M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.63M |
